BRAF and melanoma: In a study on human melanoma cells with constitutive BRAF activation (BRAFV600E), Khamari et al., explored potential metabolic changes promoting resistance (A375RIV1 cells) or sensitivity (A375-v cells) to the BRAF inhibitor Vemurafenib, by using an in vivo long-term treated xenograft mouse model.